Nirmatrelvir
| CAS No. | 2628280-40-8 |
|---|---|
| MDL No. | MFCD34473213 |
| MF | C23H32F3N5O4 |
| MW | 499.50 |
| InChI Key | LIENCHBZNNMNKG-OJFNHCPVSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Nirmatrelvir is an azabicyclohexane, specifically (1R,5S)-3-azabicyclo[3.1.0]hexane substituted with {(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}aminoacyl, 3-methyl-N-(trifluoroacetyl)-L-valinamide, methyl groups at positions 2S, 3, and 6. It is the first orally administered inhibitor of SARS-CoV-2 main protease developed by Pfizer, used in combination with ritonavir for COVID-19 treatment. It functions as an EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor and an anticoronaviral agent. It is a nitrile, a pyrrolidin-2-one, a secondary and tertiary carboxamide, a pyrrolidinecarboxamide, and an organofluorine compound.
| CAS No. | 2628280-40-8 |
|---|---|
| Product Name | Nirmatrelvir |
Associated Conditions
COVID-19·long COVID-19·kidney disease·influenza·liver disease·
* The information provided here is compiled from public sources and is for reference only.
